11 citations
,
January 2009 in “World Journal of Gastroenterology” A woman with both Cronkhite-Canada syndrome and myelodysplastic syndrome improved significantly with corticosteroid treatment.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
4 citations
,
March 2012 in “Annals of oncology” New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
1 citations
,
May 2023 in “Frontiers in Pharmacology” Genetic screening for NUDT15 polymorphisms is crucial for patients taking azathioprine, especially in Asians.
3 citations
,
December 2011 in “Pediatric Dermatology” The patient's long-term hair loss was caused by leukemia treatments and low estrogen levels, worsened by her genetic tendency for hair loss.
January 2023 in “Discovery medicine” Cepharanthine helps reduce cell aging caused by the cancer drug Doxorubicin by boosting cell cleanup processes.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
126 citations
,
November 1987 in “The Journal of Pediatrics” Selenium deficiency can cause skin and hair color loss, muscle weakness, and blood cell changes, but these improve with selenium supplements.
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
5 citations
,
April 1984 in “Archives of Dermatology” Porphyria cutanea tarda causes skin issues due to an enzyme deficiency.
5 citations
,
February 2022 in “Supportive Care in Cancer” Older age is the main risk factor for hemorrhagic cystitis after stem cell transplants.
10 citations
,
May 2011 in “American Journal of Hematology” Vinblastine can help treat childhood ITP but may cause reversible side effects.
Chemotherapy for breast cancer often causes significant and lasting hair loss.
1 citations
,
November 2021 in “Oman Medical Journal” Cyclosporine A treatment caused rare hair repigmentation in a 65-year-old man.
1 citations
,
December 2013 in “Balkan Journal of Medical Genetics” Cystic fibrosis can cause unusual symptoms like hair color changes, which can improve with proper treatment.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
13 citations
,
January 2020 in “Annals of Oncology” Cryotherapy and compression therapy might help prevent chemotherapy nerve damage, but more research is needed.
6 citations
,
October 1983 in “PubMed” Coenzyme Q10 may protect liver function but doesn't reduce hair loss from anthracycline antibiotics.
May 2018 in “European Journal of Dermatology” Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
July 2025 in “Journal of Investigative Dermatology”
23 citations
,
June 1950 in “American journal of diseases of children” Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.
1 citations
,
October 2024 in “Journal of Clinical Immunology” Vaccines work well in Netherton syndrome patients, similar to healthy people.
April 2016 in “Journal of The American Academy of Dermatology” Using a niacinamide cream can improve life quality for breast cancer patients during chemotherapy.
68 citations
,
May 2012 in “Annals of Oncology” Some breast cancer chemotherapy can cause permanent hair loss.
October 2025 in “Journal of the Endocrine Society” Methimazole can cause severe low platelet count in Graves' disease patients, so monitoring and alternative treatments are important.
55 citations
,
June 1987 in “PubMed” Cyclosporin A significantly increases hair growth in certain areas of mice.
January 2026 in “Case Reports in Dermatological Medicine” Intralesional steroids effectively treated a young female's scalp nodules without recurrence.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.